Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Understanding Hologic (HOLX) Reliance on International Revenue
Evaluate Hologic's (HOLX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock?
Women's health device maker, Hologic HOLX, slashed its earnings forecast for the full fiscal 2025, even as the latest second-quarter results topped expectations. The revenue target of $4.05-$4.10 billion remained the same as stated during the February earnings call, reflecting the $100 million cut from the initial guidance.
Hologic: Soft Performance, But Cheap Enough
Hologic, Inc.'s appeal has increased due to reduced debt, serial buybacks, and modest valuations, despite recent negative organic growth and pricey acquisitions. The company has shown solid long-term growth, reducing leverage significantly and buying back shares, but recent performance has been soft with flattish sales and earnings. Despite a slight cut in earnings guidance and soft organic growth, Hologic's shares now trade at attractive multiples with very manageable leverage.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Hologic Q2 Earnings & Revenues Top, '25 EPS View Lowered, Stock Down
HOLX delivers earnings and revenue beat in the second quarter of fiscal 2025 amid macroeconomic turbulence.
Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript
Hologic, Inc. (NASDAQ:HOLX ) Q2 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Mike Watts - Corporate VP, IR Steve MacMillan - Chairman, President & CEO Essex Mitchell - COO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Anthony Petrone - Mizuho Group Lu Li - UBS Casey Woodring - JP Morgan Conor McNamara - RBC Capital Andrew Cooper - Raymond James Mason Carrico - Stephens Operator Good afternoon, and welcome to Hologic's Second Quarter Fiscal 2025 Earnings Conference Call. My name is Rachel, and I'm your operator for today's call.
Hologic (HOLX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Hologic (HOLX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Hologic (HOLX) Tops Q2 Earnings and Revenue Estimates
Hologic (HOLX) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.03 per share a year ago.
Insights Into Hologic (HOLX) Q2: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
GYN Surgical Division Likely to Drive Hologic's Q2 Earnings
HOLX's second-quarter fiscal 2025 performance is likely to have benefited from expanding breast health offerings.
Hologic Set to Report Q2 Earnings: Buy, Sell or Hold the Stock?
Molecular Diagnostics is likely to have aided HOLX's performance in the second quarter of fiscal 2025.
